OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Brunner on the Utilization of Advanced Imaging Modalities in R/R Multiple Myeloma

March 17th 2023

Matthew Brunner, MD, discusses how to best approach the navigation of advanced imaging modalities in relapsed/refractory multiple myeloma.

Dr. Mukherjee on Maintenance Rituximab in MCL

March 17th 2023

Akash Mukherjee, MD, discusses the use of post-transplant maintenance rituximab in patients with mantle cell lymphoma who have received autologous stem cell transplant and considerations for using bendamustine/rituximab or BR plus cytarabine in elderly patients who are unfit for transplant.

Dr. Brown on the Use of PARP Inhibitors in the Upfront and Recurrent Settings in Ovarian Cancer

March 17th 2023

Jubilee Brown, MD, professor, director, gynecologic oncology, Levine Cancer Institute, Atrium Health, discusses benefits associated with PARP inhibitor maintenance therapy in the upfront and recurrent settings of ovarian cancer.

Dr. Wright on the Benefit of Moderate Hypofractionation in Early-Stage Breast Cancer

March 16th 2023

Jean Wright, MD, discusses the benefit of moderate hypofractionation in patients for adjuvant radiotherapy in patients with early-stage breast cancer.

Dr. Cai on Disparities in Access to Care in Breast Cancer

March 16th 2023

Steven Cai, MD, FACS, discusses the ongoing effort to address disparities in breast cancer care, and the importance of improving access to care for underserved patients.

Dr. Muss on the Use of Metronomic Chemotherapy in Metastatic Breast Cancer

March 16th 2023

Hyman B. Muss, MD, discusses the use of metronomic chemotherapy in metastatic breast cancer.

Dr. Fountzilas on Molecular Characterization in mCRC

March 16th 2023

Christos Fountzilas, MD, FACP, discusses findings from a study of molecular characterization in patients with colorectal cancer treated with cetuximab, an EGFR inhibitor, and pembrolizumab, a PD-1 inhibitor.

Dr. Yu on the Use of PARP Inhibitors and Radiopharmaceuticals in Prostate Cancer

March 16th 2023

Evan Y. Yu, MD, discusses new data and continuing conversations regarding the use of PARP inhibitors and targeted radioligand therapies in prostate cancer.

Dr. Carducci on the Ongoing CAPItello-280 Trial in mCRPC

March 16th 2023

Michael A. Carducci, MD, discusses the significance of two ongoing clinical trials in prostate cancer: the phase 3 CAPItello-280 trial (NCT05348577) and phase 3 INDICATE study (EA8191; NCT04423211).

Dr. Epstein-Peterson on Disease Observation and TP53 Mutations in MCL

March 16th 2023

Zachary Epstein-Peterson, MD, discusses important updates in mantle cell lymphoma treatment, including the safety and feasibility of disease observation in patients with indolent MCL and the treatment of patients with TP53-mutated MCL.

Dr. Cookson on Understanding Predictive Features in the Management of Prostate Cancer

March 15th 2023

Michael S. Cookson, MD, MMHC, discusses how understanding the relationship between key predictive factors and disease progression can help better inform the overall management of prostate cancer.

Dr. Cohen on the Use of CAR T-cell Therapy in Earlier Lines of Multiple Myeloma Treatment

March 15th 2023

Adam D. Cohen, MD, discusses the current landscape of treatment options in multiple myeloma, and elaborates on attempts to utilize these options in earlier lines of therapy.

Dr. Santos on the Current Treatment Landscape in Squamous Cell Carcinoma of the Lung

March 15th 2023

Edgardo S. Santos, MD, FACP, discusses the current treatment landscape for patients with squamous cell carcinoma of the lung.

Dr. Phillips on BTK Inhibitor Selection in MCL

March 15th 2023

Tycel Phillips, MD, MPH, discusses how to approach selecting BTK inhibitors for patients with mantle cell lymphoma and treatment decisions following disease progression on a BTK inhibitor.

Dr. Sharma on Optimal Systemic Therapy for Early-Stage TNBC

March 15th 2023

Priyanka Sharma, MD, discusses updates in optimal systemic therapy strategies in early-stage triple-negative breast cancer.

Dr. Dalal on Graft Failure in Pediatric Non-malignant Disorders

March 15th 2023

Mansi Dalal, MD, discusses findings from a study investigating graft failure risk factors in pediatric patients receiving allogeneic hematopoietic stem cell transplant for non-malignant disorders.

Dr. Milner on Hematopoietic Stem Cell Transplant in Aplastic Anemia

March 15th 2023

Jordan B. Milner, MD, discusses findings from a study evaluating the use of hematopoietic stem cell transplant up front or as salvage therapy after unsuccessful immunosuppressive therapy in pediatric patients with severe aplastic anemia.

Dr. Patel on the Association Between Ki-67 and Race in Early Breast Cancer

March 14th 2023

Rima Patel, MD, discusses the associations between the 21-gene oncotype DX recurrence score, Ki-67, and race in early-stage breast cancer.

Dr. D'Ambrosio on the Rationale of Accelerated Partial Breast Irradiation in HR+ Breast Cancer

March 14th 2023

David D'Ambrosio, MD, discusses the benefit of utilizing adjuvant accelerated partial breast irradiation, as well as a phase 2 trial investigating robotic stereotactic adjuvant accelerated partial breast irradiation for hormone receptor–positive, postmenopausal, early-stage breast cancer.

Dr. Rimm on the Use of Multiplex Spatial Proteomic Profiling in Breast Cancer

March 14th 2023

David Rimm, MD, PhD, discusses both the use and advantages of utilizing multiplex spatial proteomic profiling in breast cancer.